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Introduction: We report outcomes for a phase II study of the
combination of weekly docetaxel and cisplatin in elderly patients
with advanced non-small cell lung cancer.
Methods: Patients with chemotherapy-naive, stage IIIB/IV, an East-
ern Cooperative Oncology Group performance status of 0 or 1, ages
70 years or older, were eligible. Chemotherapy consisted of cisplatin
(25 mg/m2) on days 1, 8, and 15 and docetaxel (20 mg/m2) on days
1, 8, and 15 every 4 weeks.
Results: Forty-six (95.8%) of the 48 patients were assessable for
response, 1 case of complete response and 18 cases of partial
response were confirmed, giving an overall response rate of 39.6%
(95% confidence interval CI, 25.7–53.5%). The median time to
progression and overall survival for all patients was 5.0 months
(95% CI, 4.1–5.7 months) and 10.9 months (95% CI, 9.6–12.2
months), respectively. The most severe hematologic adverse event
was anemia, which occurred with grade 3 intensity in 6 (13.0%)
patients and grade 4 in 2 (4.3%) patients. Neutropenia occurred with
grade 3 intensity in 4 (8.7%) patients. Grade 3 asthenia, diarrhea,
neuropathy, stomatitis, and nausea/vomiting were observed in 2
(4.3%), 5 (10.9%), 5 (10.9%), 5 (10.9%), and 3 (6.5%) patients,
respectively. Yet, no grade 4 nonhematologic toxicity was observed.
Conclusions: The combination of weekly docetaxel and cisplatin is
a well-tolerated treatment modality with encouraging activity and
survival outcome in previously untreated elderly patients with ad-
vanced non-small cell lung cancer.
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The incidence of lung cancer in 2007 is estimated to be213,380 with 160,390 deaths in the United States. It will
contribute to 31% of male and 26% of female cancer-related
deaths and is the largest cause of cancer-related mortality in
both men and women.1 Forty-two percent of those patients
who are newly diagnosed with non-small cell lung cancer
(NSCLC) are older than 65 years, and one third to half are
older than 70 years.2,3
The use of chemotherapy in patients with advanced
NSCLC has been shown to improve quality of life, symptom
control, median survival, and 1-year survival rates when
compared with best supportive care.4–7 The use of palliative
chemotherapy in the elderly population has been questioned
due to the perception that elderly patients may have a higher
incidence of comorbidities, and may be less tolerant of the
chemotherapy-associated toxicity. This perception has been
compounded by the fact that elderly patients are frequently
under represented in cooperative group trials,8 thus, there is
limited data in this patient population from which to evaluate
the efficacy and toxicity of chemotherapy treatment.
Docetaxel has demonstrated antitumor activity in
NSCLC patients with chemotherapy-naive lesions and tumor
progression after receiving cisplatin-based regimens.9–13 This
drug also showed activity as a single agent in untreated
elderly advanced NSCLC patients.14 In the first line setting,
docetaxel demonstrated both an interesting activity and effi-
cacy whether combined with a platinum compound.15 Do-
cetaxel with cisplatin is one of the common chemotherapy
regimens for NSCLC. The commonly used dose and schedule
of docetaxel is 60 to 100 mg/m2 every 3 weeks; however,
moderate to severe neutropenia is frequently observed.9–13,16
Several studies have shown that weekly administration of
docetaxel produces a higher dose intensity and less myelo-
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toxicity.17–19 Based on these favorable results, we conducted
the present phase II study to evaluate the safety, efficacy, and
tolerability of the combination of weekly docetaxel and
cisplatin in elderly patients with advanced NSCLC.
PATIENTS AND METHODS
Patient Selection
Patients with histologically and/or cytologically docu-
mented NSCLC were eligible for the study. Each patient was
required to meet the following criteria: clinical stage IV or
IIIB (including only patients with no indications for curative
radiotherapy), an Eastern Cooperative Oncology Group per-
formance status (PS) of 0 or 1, age 70 years, no prior
chemotherapy, measurable lesions, adequate hematological
function (white blood cell count 4000 to 12,000/mm3; neu-
trophils 2000/mm3; platelets 100,000/mm3; hemoglobin
9.0 g/dl), adequate hepatic function (total bilirubin 1.1
mg/dl, aspartate aminotransferase and alanine aminotransfer-
ase 60 IU/liter), and adequate renal function (creatinine
1.2 mg/dl, creatinine clearance 60 ml/min). Patients with
active infection, severe heart disease, uncontrollable hyper-
tension or diabetes mellitus, active concomitant malignancy
and pleural and/or pericardial effusion requiring drainage
were excluded. The institutional review board of each au-
thor’s institution approved the protocol, and written informed
consent was obtained from all patients before enrollment.
Patient Evaluation
The pretreatment evaluation consisted of complete
blood cell count, differential count, routine chemistry mea-
surements, a chest radiograph, a chest computed tomography
(CT) scan, abdominal ultrasound or CT scan, whole-brain
magnetic resonance imaging or CT scan, and an isotope bone
scan. Complete blood cell count, differential, count and
routine chemistry measurements were carried out at least
twice a week during the first course of chemotherapy.
Treatment Schedule
All patients were admitted to hospital during the first
course of chemotherapy. Chemotherapy consisted of cisplatin
(25 mg/m2) on days 1, 8, and 15 and docetaxel (20 mg/m2) on
days 1, 8, and 15 every 4 weeks. Docetaxel was infused over
30 minutes with 16 mg dexamethasone and 3 mg granisetron
administered just before the docetaxel infusion. Ninety min-
utes after the completion of the docetaxel infusion, 25 mg/m2
cisplatin were administered over 15 minutes with 1500 ml
normal saline over 3.5 hours. Cisplatin was administered
along with a program of forced diuresis that included at least
2000 ml fluids on days 2 to 3.
Dose adjustments at the start of a new cycle were based
on the worst toxicity observed during the previous cycle. For
hematologic toxicity, subsequent cycles were delayed for up
to 2 weeks if grade 2 toxicities appeared. The dose of
docetaxel was reduced to 80% if grade 4 myelosuppression or
febrile neutropenia was present, and if myelosuppression or
febrile neutropenia persisted an additional reduction of do-
cetaxel dose to 60% was required. If there was a third such
episode docetaxel was discontinued. In the case of grade 2
nonhematologic toxicity, treatment was delayed until recov-
ery but not for more than 2 weeks. The dose was reduced in
the case of severe nonhematologic toxicity that was not
controllable with usual measures, and treatment was discon-
tinued if the patient experienced a significant hypersensitivity
reaction or unacceptable toxicity (e.g., grade 4 stomatitis or
diarrhea, grade 3 peripheral neuropathy, severe and persis-
tent skin/nail changes). Docetaxel administration could be
omitted if one of the following toxicities was noted on day 8
or day 15: grade 2 hematologic or nonhematologic toxici-
ties, fever 38°C, diarrhea of any grade, or a decreased PS.
Dose adjustment criteria for cisplatin were based on creati-
nine clearance, which was calculated before the beginning of
each cycle, and neuropathy. The dose of cisplatin could be
reduced to 80% for a reversible decrease of creatinine clear-
ance. Cisplatin was also reduced to 80% if grade 2 neurop-
athy appeared.
Chemotherapy was administered for up to six cycles
unless there was documented disease progression, unaccept-
able toxicity, or patient refusal. The prophylactic administra-
tion of G-CSF was not permitted. Administration of G-CSF
was permitted in patients with grade 4 neutropenia and/or
leukopenia or grade 3 febrile neutropenia. Second-line treat-
ments were permitted at the investigators’ discretion and the
nature of any second-line treatments was recorded.
Response to Treatment and Adverse Effects
After every two cycles of treatment, response was
evaluated using RECIST criteria. Of the lesions observed
before treatment, a maximum of five measurable lesions from
each metastasized organ up to a total of 10 lesions were
selected as target lesions. In cases of partial or complete
response (CR), a confirmative CT scan was performed 4
weeks later and this was followed by a CT scan after every
two treatment cycles. Toxicity was reported using a National
Cancer Institute-Common Toxicity Criteria version 2.0 tox-
icity scale.
Statistical Analysis
The current trial used a two-stage optimal design, as
proposed by Simon,20 with an 80% power to accept the
hypothesis and 5% significance to reject the hypothesis. Plus,
the current trial was designed to detect a response rate of 40%
as compared with a minimal, clinically meaningful response
rate of 20%. Allowing for a follow-up loss rate of 10%, the
total sample size was 48 patients with a measurable disease.
All enrolled patients were included in the intention-to-treat
analysis of efficacy. The duration of response, time to pro-
gression (TTP), and survival analyses were all estimated
using the Kaplan–Meier method. The duration of response
was defined as the interval from the onset of a CR or partial
response until evidence of disease progression was found.
Meanwhile, the TTP was calculated from the initiation of
chemotherapy to the date of disease progression, while over-
all survival was measured from the initiation of chemother-
apy to the date of the last follow-up or death. The statistical
data were obtained using an SPSS software package (SPSS
11.5 Inc., Chicago, IL).
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RESULTS
Patient Characteristics
From June 2004 to July 2006, a total of 48 patients
were enrolled in the current study from 5 centers. The
characteristics of the patients are summarized in Table 1. The
median age was 76 (range, 70–86) years, with 30 males and
18 females. Thirty-four (70.8%) patients had a metastatic
disease, while 14 patients had a recurrent disease after sur-
gical resection (pulmonary resection) of the primary tumor.
Distal lymph nodes and bone were the most common sites of
the metastases. No patients had received prior chemotherapy
or radiotherapy.
Efficacy and Survival
Forty-six (95.8%) of the 48 patients were assessable for
response, of the two patients not assessable, one was lost to
follow-up after the first cycle of the treatment, and the other
died after the first cycle of unknown cause, although brain
metastasis was suspected. All efficacy data are reported using
the intent-to-treat patient population. Disease control (objec-
tive response and stable disease) in the ITT population was
achieved in 83.3% of patients. One case of CR and 18 cases
of partial response were confirmed, giving an overall re-
sponse rate of 39.6% (95% CI, 25.7–53.5%) (Table 2). Of 19
responses, 4 (21.1%) were observed after 3 cycles, 12
(63.2%) after 4 cycles and 3 (15.8%) after 6 cycles. The
median follow-up period was 12.4 months. The median TTP
for all patients was 5.0 months (95% CI, 4.1–5.7 months)
(Figure 1). Forty-four patients had died at the time of the
present evaluation. The estimated median overall survival
was 10.9 months (95% CI, 9.6–12.2 months) (Figure 2).
Toxicity
A total of 148 cycles were administered in 46 patients
assessable for toxicity, with a median of 3 cycles per patient
(range 1–6 cycles). The occurrence and the incidence of the
hematologic and nonhematologic toxicities are shown in
Table 3. The most severe hematologic adverse event was
anemia, which occurred with grade 3 intensity in 6 (13.0%)
patients and grade 4 in 2 (4.3%) patients. Neutropenia oc-
curred with grade 3 intensity in 4 (8.7%) patients. However,
FIGURE 1. Time to disease progression for all patients.
TABLE 1. Patient Characteristics
Characteristics No. of Patients n (%)
Patients enrolled 48
Sex
Male 30 (62.5)
Female 18 (37.5)
Age at diagnosis (years)
Median (range) 76 (70–86)
75 23 (47.9)
75 25 (52.1)
Histologic type
Adenocarcinoma 25 (52.1)
Squamous cell carcinoma 20 (41.7)
Large cell carcinoma 3 (6.3)
ECOG performance status
0 11 (22.9)
1 37 (77.1)
Disease stage
Stage IIIb/recurrent 14 (29.2)
Stage IV/metastatic 34 (70.8)
No. of involved site(s)
1 6 (12.5)
2 19 (39.6)
3 23 (47.9)
Metastatic site(s)a
Lung 43 (89.6)
Liver 8 (16.7)
Pleura 7 (14.6)
Bone 18 (37.5)
Lymph nodes 34 (70.8)
Adrenal 8 (16.7)
Other viscera 7 (14.6)
a Because patients could have metastases at multiple sites, the total numbers of
metastases are greater than the number of patients.
ECOG, Eastern Cooperative Oncology Group.
TABLE 2. Tumor Response (Intention-to-Treat Analysis,
n  48)
Response n (%)
Overall response rate (ORR) 19 (39.6)a
Complete response (CR) 1 (2.1)
Partial response (PR) 18 (37.5)
Stable disease (SD) 21 (43.8)
Progressive disease (PD) 6 (12.5)
CR  PR  SD 40 (83.3)
Not assessable 2 (4.2)
a 95% confidential interval (CI)  25.7–53.5%.
ORR, overall response rate; CR, complete response; PR, partial response; SD,
stable disease; PD, progressive disease.
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no grade 4 Neutropenia was observed. Stomatitis, nausea/
vomiting, neuropathy, and asthenia were the most common
nonhematological toxicities. Grade 1/2 nausea/vomiting, neu-
ropathy, asthenia, and stomatitis were observed in 23
(50.0%), 20 (43.5%), 17 (37.0%), and 13 (28.2%) patients,
respectively. And grade 3 asthenia, diarrhea, neuropathy,
stomatitis, and nausea/vomiting were observed in 2 (4.3%), 5
(10.9%), 5 (10.9%), 5 (10.9%), and 3 (6.5%) patients. Yet, no
grade 4 nonhematologic toxicity was observed. Overall, treat-
ment was delayed or the dose reduced in 24 (16.2%) and 15
(10.1%) cycles, respectively. Four patients were hospitalized
because of treatment toxicities (three because of infections
and one because of general weakness). There were no treat-
ment-related deaths during this study.
Second-Line Treatment
Salvage treatment was not specified in the protocol.
Palliative radiotherapy was given to six patients with symp-
tomatic progression in lung, bone, or brain. We offered
second-line chemotherapy to 35 patients after failure. Sec-
ond-line therapy after docetaxel plus cisplatin was mostly
nonplatinum therapy: 12 patients received gemcitabine-based
therapy, 4 patients received irinotecan, 19 patients were
treated with gefitinib or erlotinib. Nine patients received
third-line treatment.
DISCUSSION
To date, the optimal regimen for fit, elderly patients is
not certain. The present trial, targeting elderly (age 70 years
and older) advanced-stage NSCLC patients, was designed to
evaluate the safety, efficacy, and tolerability of the combina-
tion of weekly docetaxel and cisplatin chemotherapy. In the
present trial, the overall response rate according to an inten-
tion to treat analysis was 39.6% that was similar to the other
previous trials21–25 (Table 4). We observed a median TTP of
5.0 months, a median overall survival of 10.9 months, which
can be considered encouraging.
Docetaxel has demonstrated antitumor activity in
NSCLC patients with chemotherapy-naive lesions and tumor
progression after receiving cisplatin-based regimens.9–13 Sev-
eral recent studies have compared weekly docetaxel to the
standard 3-weekly schedule.26,27 In a Spanish randomized
phase III trial,26 259 patients from 33 centers were random-
ized to receive either docetaxel 75 mg/m2 every 3 weeks or
docetaxel 36 mg/m2 weekly for 6 weeks followed by 2 weeks
of rest. Febrile neutropenia was significantly more frequent in
the standard treatment arm but more patients in the weekly
arm experienced mycosis’s. Another randomized phase III
study27 compared a weekly schedule (33.3 mg/m2 for 6
weeks) to the standard dose (75 mg/m2) in patients75 years
of age with an Eastern Cooperative Oncology Group PS 2.
No difference in the global quality of life scores was found at
3 weeks. Pain, cough, and hair loss were significantly milder
with the weekly schedule, while diarrhea was worse. Loss of
appetite and overall health were significantly worse in the
3-week arm during the first week, while nausea and loss of
appetite were more severe in the weekly arm during the third
week. Grade 3–4 hematologic toxicity was significantly more
frequent in the standard arm. At higher doses (40 mg/m2)
weekly administration remains significantly less toxic with
respect to grade 3/4 leukopenia and neutropenia, but drug-
induced pneumonitis is more frequent.28,29 A recent litera-
ture-based meta-analysis30 selected 6 randomized clinical
trials (three phase III, 2 phase II, 1018 patients) and con-
firmed these results, with a significant advantage of weekly
docetaxel with respect to grade 3/4 neutropenia (absolute
benefit of 15–19%, without a survival improvement). In the
3-week schedule, even with a lower dose (60 mg/m2), grade
3/4 neutropenia remained frequent (86.7% in the study by
Takkakaw et al.31). To examine the effects of chemotherapy
FIGURE 2. Overall survival for all patients.
TABLE 3. Adverse Reactions (By Patients, n  46)
Gradea n (%)
1 2 3 4
Hematologic
Anemia 14 (30.4) 9 (19.6) 6 (13.0) 2 (4.3)
Neutropenia 9 (19.6) 7 (15.2) 4 (8.7) 0
Thrombocytopenia 5 (10.9) 3 (6.5) 0 0
Nonhematologic
Nausea/vomiting 13 (28.3) 10 (21.7) 3 (6.5) 0
Stomatitis 7 (15.2) 6 (13.0) 5 (10.9) 0
Diarrhea 4 (8.7) 3 (6.5) 5 (10.9) 0
Asthenia 4 (8.7) 13 (28.3) 2 (4.3) 0
Constipation 3 (6.5) 1 (2.2) 0 0
Edema 5 (10.9) 3 (6.5) 0 0
Neuropathy 13 (28.3) 7 (15.2) 5 (10.9) 0
Nail 3 (6.5) 6 (13.0) 4 (8.7) 0
Skin 3 (6.5) 2 (4.3) 1 (2.2) 0
Lacrimation 9 (19.6) 4 (8.7) 2 (4.3) 0
Elevated transaminase 1 (2.2) 1 (2.2) 0 0
Elevated creatinine 2 (4.3) 1 (2.2) 0 0
Hyperbilirubin anemia 1 (2.2) 1 (2.2) 0 0
a NCI CTC version 2.0.
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in elderly patients (65 years) further, Bellini and Fossella32
conducted preplanned subgroup analyses of patients age 65
and 65 years enrolled in the multinational, randomized
phase II study of TAX 326, found that elderly patients
tolerated docetaxel-platinum well despite experiencing
slightly more toxicity than younger patients.
Hematological and nonhematological toxicities were
mild and acceptable in our study. The compliance to treat-
ment was in general good. In particular, the present trial
confirms that a modified schedule of docetaxel (20 mg/m2)
and cisplatin (25 mg/m2) on days 1, 8, and 15 every 4 weeks
is feasible and well tolerated in elderly advanced NSCLC
patients.22 Our tolerability data confirm the previous obser-
vations that weekly docetaxel is advantageous in terms of
hematological toxicity with respect to 3-weekly sched-
ule.26,27,33,34 A possible approach to reduce the toxicity of
combination regimens consists of administering the same
drugs in a sequential manner. This strategy may allow the
administration of full dose single agents sequentially without
compromising efficacy, while reducing potential toxicity ex-
pected with concurrent administration. Preclinical models35,36
as well as recent clinical trial in NSCLC suggest a benefit for
the sequential administration of chemotherapy agents. We
divided the cisplatin and docetaxel dosages on days 1, 8, and
15 because full-dose cisplatin is too toxic for elderly patients.
The weekly administration of docetaxel produces a higher
dose intensity and less myelotoxicity.17–19,22 Moreover, a
weekly schedule may be safer than a 3-weekly schedule
because treatment on day 8 and/or day 15 can be omitted if
severe toxicity is observed. In the current study, the toxicity,
including nausea/vomiting and renal toxicity, was relatively
mild, and 92% of the planned administrations were carried
out. The dose-limiting toxicities of docetaxel administered in
six consecutive weekly infusions were reported to be fatigue
and asthenia.17–19 However, fatigue and asthenia were rela-
tively mild in our study because of the relatively low-dose of
docetaxel (20 mg/m2), similar as the previous study.22 At the
time of beginning of this study, the updated American Soci-
ety of Clinical Oncology guidelines for the treatment of
unrespectable NSCLC was published in January 2004.37 Rec-
ognizing that the optimal duration of chemotherapy remains
a matter of debate, Pfizer et al. noted that prolonged chemo-
therapy can lead to cumulative toxicity, with no proven
advantage in efficacy. In fact, the majority of patients failed
to have a major response, or became intolerant of chemother-
apy, by the third or fourth cycle. Furthermore, in light of new
evidence that supports the use of second-line chemotherapy at
the time of recurrence, the Panel consensus was to change the
prior recommendation, and advocate no more than six cycles
of initial chemotherapy, even in patients who have responded
to treatment. We conducted this trial of six cycles, even some
evidence does not demonstrate any advantage of platinum
based chemotherapy after four cycles.38
In conclusion, the combination of weekly docetaxel and
cisplatin is a well-tolerated treatment modality with encour-
aging activity and survival outcome in previously untreated
elderly patients with advanced NSCLC. Whether the combi-
nation in this population is superior to the other regimens
should be compared in a phase III trial.
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